Asthma remains a significant global health challenge, affecting nearly 18% of the population. Characterized by chronic airway inflammation, mucus hypersecretion, and airway hyper-responsiveness (AHR), the disease's underlying molecular mechanisms are still being unraveled. While standard therapies provide relief for many, a subset of patients requires more targeted interventions. Recent research has highlighted Follistatin-like protein 1 (FSTL1) as a potential mediator in inflammatory disorders. This study investigates the role of FSTL1 in allergic airway inflammation and its interaction with the NLRP3 inflammasome.
Clinical Evidence: FSTL1 and IL-1β in Asthma
The study first examined the clinical relevance of FSTL1 by analyzing serum samples from 30 asthmatic patients and 30 healthy controls. The results revealed that both FSTL1 and Interleukin-1β (IL-1β) levels were significantly elevated in the asthmatic group. Notably, a strong positive correlation was found between circulating FSTL1 and IL-1β levels (r = 0.749, P < 0.0001), suggesting that FSTL1 may drive the production of this potent inflammatory cytokine in asthma.
Experimental Validation in Mouse Models
To determine if FSTL1 is actively involved in disease progression, researchers utilized an Ovalbumin (OVA)-induced asthma model in mice. They compared wild-type (WT) mice with $Fstl1^{+/-}$ heterozygous mice, which have reduced FSTL1 expression.
The findings were striking: FSTL1 deficiency significantly ameliorated the hallmarks of asthma. $Fstl1^{+/-}$ mice exhibited:
- Reduced Airway Hyper-responsiveness: Lower lung resistance (RL) compared to WT mice after allergen exposure.
- Decreased Inflammatory Infiltration: A significant reduction in the number of eosinophils and other inflammatory cells in the bronchoalveolar lavage fluid (BALF).
- Less Tissue Damage: Histological analysis (H&E and PAS staining) showed reduced inflammatory cell infiltration around the airways and decreased mucus production in the lungs of $Fstl1^{+/-}$ mice.
- Lower Cytokine Levels: Reduced levels of Th2-associated cytokines, including IL-5 and IL-13, in the BALF.
The NLRP3 Inflammasome Mechanism
The study further explored the molecular pathway through which FSTL1 exerts its effects. The NLRP3 inflammasome is a multi-protein complex that, when activated, triggers the cleavage of pro-caspase-1 into its active form, leading to the maturation and release of IL-1β.
In vitro experiments using primary peritoneal macrophages showed that FSTL1 stimulation increased NLRP3 expression in a dose-dependent manner. Furthermore, FSTL1 promoted the self-cleavage of pro-caspase-1. The importance of this pathway was confirmed using MCC950, a selective NLRP3 inhibitor, which successfully blocked FSTL1-induced inflammasome activation and attenuated airway inflammation both in vivo and in vitro.
Conclusion and Therapeutic Potential
This research identifies FSTL1 as a pro-inflammatory molecule in the context of asthma, rather than the cardioprotective role it plays in other tissues. By activating the NLRP3 inflammasome, FSTL1 triggers a cascade of inflammatory signals that exacerbate airway symptoms. These findings suggest that targeting the FSTL1-NLRP3 axis could offer a novel therapeutic strategy for patients with allergic airway inflammation, particularly those who do not respond adequately to current standard treatments.
Future studies are needed to identify the specific receptors involved in FSTL1 uptake and to determine if these findings apply across different asthma phenotypes.
Summary updated